ID   SK-MEL-100
AC   CVCL_6067
SY   SK-Mel-100; SK-MEL 100; SK-Mel 100; SKMEL-100; SKMEL100; DY-Mel
DR   cancercelllines; CVCL_6067
DR   Cosmic; 685206
DR   Cosmic; 721848
DR   Cosmic; 1122257
DR   Cosmic; 1507611
DR   Cosmic; 1669160
DR   Cosmic; 2233670
DR   Cosmic; 2440476
DR   GEO; GSM555126
DR   GEO; GSM555179
DR   GEO; GSM784522
DR   Lonza; 1336
DR   Progenetix; CVCL_6067
DR   Wikidata; Q54953756
RX   PubMed=2983346;
RX   PubMed=6933476;
RX   PubMed=7747814;
RX   PubMed=15299072;
RX   PubMed=21343389;
RX   PubMed=21725359;
RX   PubMed=24576830;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=2983346; DOI=10.1073/pnas.82.5.1470;
RA   Dracopoli N.C., Houghton A.N., Old L.J.;
RT   "Loss of polymorphic restriction fragments in malignant melanoma:
RT   implications for tumor heterogeneity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985).
//
RX   PubMed=6933476; DOI=10.1073/pnas.77.7.4260;
RA   Houghton A.N., Taormina M.C., Ikeda H., Watanabe T., Oettgen H.F.,
RA   Old L.J.;
RT   "Serological survey of normal humans for natural antibody to cell
RT   surface antigens of melanoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980).
//
RX   PubMed=7747814;
RA   Gruis N.A., Weaver-Feldhaus J.M., Liu Q.-Y., Frye C., Eeles R., Orlow I.,
RA   Lacombe L., Ponce-Castaneda V., Lianes P., Latres E., Skolnick M.H.,
RA   Cordon-Cardo C., Kamb A.;
RT   "Genetic evidence in melanoma and bladder cancers that p16 and p53
RT   function in separate pathways of tumor suppression.";
RL   Am. J. Pathol. 146:1199-1206(1995).
//
RX   PubMed=15299072; DOI=10.1158/1535-7163.895.3.8;
RA   Qin J.-Z., Stennett L., Bacon P., Bodner B., Hendrix M.J.C.,
RA   Seftor R.E.B., Seftor E.A., Margaryan N.V., Pollock P.M., Curtis A.,
RA   Trent J.M., Bennett F., Miele L., Nickoloff B.J.;
RT   "p53-independent NOXA induction overcomes apoptotic resistance of
RT   malignant melanomas.";
RL   Mol. Cancer Ther. 3:895-902(2004).
//
RX   PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958;
RA   Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M.,
RA   Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R.,
RA   Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E.,
RA   Ostrer H., Osman I.;
RT   "Integrative genomics identifies molecular alterations that challenge
RT   the linear model of melanoma progression.";
RL   Cancer Res. 71:2561-2571(2011).
//
RX   PubMed=21725359; DOI=10.1038/onc.2011.250;
RA   Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M.,
RA   She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I.,
RA   Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G.,
RA   Wolchok J.D., Houghton A.N., Solit D.B.;
RT   "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF
RT   dependence in melanomas harboring (V600E)BRAF.";
RL   Oncogene 31:446-457(2012).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//